Vildagliptin

spinqualitylabelsall models Vildagliptin, better known as Galvus, ([[___]]) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image

Better Known as: Galvus

• Marketed By:
• Major Indication:
• Drug Class:
• Date of FDA Approval (Patent Expiration):
• 2009 Sales:
• Importance:
• See Pharmaceutical Drugs for more information about other drugs and diseases.

Pharmacokinetics

DPP4 Inhibitor Pharmacokinetics Parameter Vildagliptin (Galvus) Sitagliptin (Januvia) Saxagliptin (Onglyza) Tmax (hr) 1.75 1-4 2 Cmax (ng/ml) 290 330 34 Bioavailability (%) 85 87 67 Protein Binding (%) 9 38 0 T1/2 (hr) 2-3 12.4 2.5 AUC (ng/ml/hr) 1610 3470 101 IC50 (nM) 3 18 50 Renal Clearance (L/h) 13.0 21.0 13.8 Volume Distribution (L) 71 198 151 Dosage (mg) 100 100 5 Metabolism Hydrolysis Hepatic (CYP3A4 & CYP2C8) Hepatic (CYP3A4) For Pharmacokinetic Data References, see: References